24 results on '"Zimatore, Giovanni Bosco"'
Search Results
2. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis
- Author
-
Boffa, Giacomo, Signori, Alessio, Massacesi, Luca, Mariottini, Alice, Sbragia, Elvira, Cottone, Salvatore, Amato, Maria Pia, Gasperini, Claudio, Moiola, Lucia, Meletti, Stefano, Repice, Anna Maria, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Filippi, Massimo, De Luca, Giovanna, Lus, Giacomo, Zaffaroni, Mauro, Sola, Patrizia, Conte, Antonella, Nistri, Riccardo, Aguglia, Umberto, Granella, Franco, Galgani, Simonetta, Caniatti, Luisa Maria, Lugaresi, Alessandra, Romano, Silvia, Iaffaldano, Pietro, Cocco, Eleonora, Saccardi, Riccardo, Angelucci, Emanuele, Trojano, Maria, Mancardi, Giovanni Luigi, Sormani, Maria Pia, Inglese, Matilde, Capobianco, Marco, Zimatore, Giovanni Bosco, Frau, Jessica, Scarpini, Elio, Meucci, Giuseppe, Guidetti, Donata, Gualandi, Francesca, Varaldo, Riccardo, Raiola, Anna Maria, Innocenti, Chiara, Zoli, Valerio, Ciceri, Fabio, Greco, Raffaella, Scim`e, Rosanna, De Gobbi, Marco, Barilaro, Alessandro, Boffa, Giacomo, Signori, Alessio, Massacesi, Luca, Mariottini, Alice, Sbragia, Elvira, Cottone, Salvatore, Amato, Maria Pia, Gasperini, Claudio, Moiola, Lucia, Meletti, Stefano, Repice, Anna Maria, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Filippi, Massimo, De Luca, Giovanna, Lus, Giacomo, Zaffaroni, Mauro, Sola, Patrizia, Conte, Antonella, Nistri, Riccardo, Aguglia, Umberto, Granella, Franco, Galgani, Simonetta, Caniatti, Luisa Maria, Lugaresi, Alessandra, Romano, Silvia, Iaffaldano, Pietro, Cocco, Eleonora, Saccardi, Riccardo, Angelucci, Emanuele, Trojano, Maria, Mancardi, Giovanni Luigi, Sormani, Maria Pia, and Inglese, Matilde
- Subjects
Hematopoietic Stem Cell Transplantation ,Active Secondary Progressive Multiple Sclerosis ,Neurology (clinical) ,Research Article - Abstract
Background and ObjectivesUncontrolled evidence suggests that autologous hematopoietic stem cell transplantation (AHSCT) can be effective in people with active secondary progressive multiple sclerosis (SPMS). In this study, we compared the effect of AHSCT with that of other anti-inflammatory disease-modifying therapies (DMTs) on long-term disability worsening in active SPMS.MethodsWe collected data from the Italian Bone Marrow Transplantation Study Group and the Italian Multiple Sclerosis Register. Patients were considered eligible if treatment had been started after the diagnosis of SPMS. Disability worsening was assessed by the cumulative proportion of patients with a 6-month confirmed disability progression (CDP) according to the Expanded Disability Status Scale (EDSS) score. Key secondary endpoints were the EDSS time trend after treatment start and the prevalence of disability improvement over time. Time to first CDP was assessed by means of proportional hazard Cox regression models. A linear mixed model with a time × treatment group interaction was used to assess the longitudinal EDSS time trends. Prevalence of improvement was estimated using a modified Kaplan-Meier estimator and compared between groups by bootstrapping the area under the curve.ResultsSeventy-nine AHSCT-treated patients and 1975 patients treated with other DMTs (beta interferons, azathioprine, glatiramer-acetate, mitoxantrone, fingolimod, natalizumab, methotrexate, teriflunomide, cyclophosphamide, dimethyl fumarate, and alemtuzumab) were matched to reduce treatment selection bias using propensity score and overlap weighting approaches. Time to first CDP was significantly longer in transplanted patients (hazard ratio [HR] = 0.50; 95% CI = 0.31–0.81;p= 0.005), with 61.7% of transplanted patients free from CPD at 5 years. Accordingly, EDSS time trend over 10 years was higher in patients treated with other DMTs than in AHSCT-treated patients (+0.157 EDSS points per year compared with −0.013 EDSS points per year; interactionp< 0.001). Patients who underwent AHSCT were more likely to experience a sustained disability improvement: 34.7% of patients maintained an improvement (a lower EDSS than baseline) 3 years after transplant vs 4.6% of patients treated by other DMTs (p< 0.001).DiscussionThe use of AHSCT in people with active SPMS is associated with a slowing of disability progression and a higher likelihood of disability improvement compared with standard immunotherapy.Classification of EvidenceThis study provides Class III evidence that autologous hematopoietic stem cell transplants prolonged the time to CDP compared with other DMTs.
- Published
- 2022
3. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
- Author
-
Iaffaldano, Pietro, Lucisano, Giuseppe, Pozzilli, Carlo, Brescia Morra, Vincenzo, Ghezzi, Angelo, Millefiorini, Enrico, Patti, Francesco, Lugaresi, Alessandra, Zimatore, Giovanni Bosco, Marrosu, Maria Giovanna, Amato, Maria Pia, Bertolotto, Antonio, Bergamaschi, Roberto, Granella, Franco, Coniglio, Gabriella, Tedeschi, Gioacchino, Sola, Patrizia, Lus, Giacomo, Ferrò, Maria Teresa, Iuliano, Gerardo, Corea, Francesco, Protti, Alessandra, Cavalla, Paola, Guareschi, Angelica, Rodegher, Mariaemma, Paolicelli, Damiano, Tortorella, Carla, Lepore, Vito, Prosperini, Luca, Saccà, Francesco, Baroncini, Damiano, Comi, Giancarlo, and Trojano, Maria
- Published
- 2015
- Full Text
- View/download PDF
4. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis
- Author
-
Boffa, Giacomo, Signori, Alessio, Massacesi, Luca, Mariottini, Alice, Sbragia, Elvira, Cottone, Salvatore, Amato, Maria Pia, Gasperini, Claudio, Moiola, Lucia, Meletti, Stefano, Repice, Anna Maria, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Filippi, Massimo, De Luca, Giovanna, Lus, Giacomo, Zaffaroni, Mauro, Sola, Patrizia, Conte, Antonella, Nistri, Riccardo, Aguglia, Umberto, Granella, Franco, Galgani, Simonetta, Caniatti, Luisa Maria, Lugaresi, Alessandra, Romano, Silvia, Iaffaldano, Pietro, Cocco, Eleonora, Saccardi, Riccardo, Angelucci, Emanuele, Trojano, Maria, Mancardi, Giovanni Luigi, Sormani, Maria Pia, Inglese, Matilde, Capobianco, Marco, Zimatore, Giovanni Bosco, Frau, Jessica, Scarpini, Elio, Meucci, Giuseppe, Guidetti, Donata, Gualandi, Francesca, Varaldo, Riccardo, Raiola, Anna Maria, Innocenti, Chiara, Zoli, Valerio, Ciceri, Fabio, Greco, Raffaella, Scim`e, Rosanna, De Gobbi, Marco, and Barilaro, Alessandro
- Published
- 2023
- Full Text
- View/download PDF
5. The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis
- Author
-
Portaccio, Emilio, primary, Bellinvia, Angelo, additional, Prestipino, Elio, additional, Nacmias, Benedetta, additional, Bagnoli, Silvia, additional, Razzolini, Lorenzo, additional, Pastò, Luisa, additional, Niccolai, Claudia, additional, Goretti, Benedetta, additional, Fonderico, Mattia, additional, Zimatore, Giovanni Bosco, additional, Losignore, Nunzia Alessandra, additional, Sorbi, Sandro, additional, and Amato, Maria Pia, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis
- Author
-
Massarotti, Claudia, primary, Sbragia, Elvira, additional, Boffa, Giacomo, additional, Vercelli, Caterina, additional, Zimatore, Giovanni Bosco, additional, Cottone, Salvatore, additional, Frau, Jessica, additional, Raiola, Annamaria, additional, Varaldo, Riccardo, additional, Mancardi, Gianluigi, additional, Inglese, Matilde, additional, and Anserini, Paola, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Correction: Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors
- Author
-
Amato, Maria Pia, primary, Prestipino, Elio, additional, Bellinvia, Angelo, additional, Niccolai, Claudia, additional, Razzolini, Lorenzo, additional, Pastò, Luisa, additional, Fratangelo, Roberto, additional, Tudisco, Laura, additional, Fonderico, Mattia, additional, Mattiolo, Paolo Luca, additional, Goretti, Benedetta, additional, Zimatore, Giovanni Bosco, additional, Losignore, Nunzia Alessandra, additional, Portaccio, Emilio, additional, and Lolli, Francesco, additional
- Published
- 2019
- Full Text
- View/download PDF
8. Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors
- Author
-
Amato, Maria Pia, primary, Prestipino, Elio, additional, Bellinvia, Angelo, additional, Niccolai, Claudia, additional, Razzolini, Lorenzo, additional, Pastò, Luisa, additional, Fratangelo, Roberto, additional, Tudisco, Laura, additional, Fonderico, Mattia, additional, Mattiolo, Paolo Luca, additional, Goretti, Benedetta, additional, Zimatore, Giovanni Bosco, additional, Losignore, Nunzia Alessandra, additional, Portaccio, Emilio, additional, and Lolli, Francesco, additional
- Published
- 2019
- Full Text
- View/download PDF
9. Prognostic indicators in pediatric clinically isolated syndrome
- Author
-
Iaffaldano, Pietro, Simone, Marta, Lucisano, Giuseppe, Ghezzi, Angelo, Coniglio, Gabriella, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Lugaresi, Alessandra, Izquierdo, Guillermo, Bergamaschi, Roberto, Cabrera-Gomez, Jose Antonio, Pozzilli, Carlo, Millefiorini, Enrico, Alroughani, Raed, Boz, Cavit, Pucci, Eugenio, Zimatore, Giovanni Bosco, Sola, Patrizia, Lus, Giacomo, Maimone, Davide, Avolio, Carlo, Cocco, Eleonora, Sajedi, Seyed Aidin, Costantino, Gianfranco, Duquette, Pierre, Shaygannejad, Vahid, Petersen, Thor, Fernández Bolaños, Ricardo, Paolicelli, Damiano, Tortorella, Carla, Spelman, Tim, Margari, Lucia, Amato, Maria Pia, Comi, Giancarlo, Butzkueven, Helmut, Trojano, Maria, Spitaleri, Daniele, Rottoli, Maria Rosa, Ardito, Bonaventura, Iuliano, Gerardo, Montanari, Enrico, Granieri, Enrico, Tedeschi, Gioacchino, Bertolotto, Antonio, Granella, Franco, Di Battista, Giancarlo, Gallo, Paolo, Cavalla, Paola, Bellantonio, Paolo, De Robertis, Francesca, Durelli, Luca, Scarpini, Elio, Rezzonico, Monica, Protti, Alessandra, Solaro, Claudio, Corea, Francesco, Bosco, Antonio, Vianello, Marika, Ferrò, Maria Teresa, Balgera, Roberto, Grasso, Roberta, De Luca, Giovanna, Farina, Deboah, Travaglini, Daniela, di Ioia, Maria, Di Tommaso, Valeria, Mancinelli, Luca, Pietrolongo, Erika, Hupperts, Raymond, Rio, Maria Edite, Terzi, Murat, Barnett, Michael, Slee, Mark, Van Pesch, Vincent, Savino, Aldo, Lechner-Scott, Jeannette, Grammond, Pierre, Singhal, Bhim, Zwanikken, Cees, Fiol, Marcela, Patrucco, Liliana, Paine, Mark, Mccombefrom, Pamela, Grand'Maison, Francois, Iaffaldano, Pietro, Simone, Marta, Lucisano, Giuseppe, Ghezzi, Angelo, Coniglio, Gabriella, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Lugaresi, Alessandra, Izquierdo, Guillermo, Bergamaschi, Roberto, Cabrera-Gomez, Jose Antonio, Pozzilli, Carlo, Millefiorini, Enrico, Alroughani, Raed, Boz, Cavit, Pucci, Eugenio, Zimatore, Giovanni Bosco, Sola, Patrizia, Lus, Giacomo, Maimone, Davide, Avolio, Carlo, Cocco, Eleonora, Sajedi, Seyed Aidin, Costantino, Gianfranco, Duquette, Pierre, Shaygannejad, Vahid, Petersen, Thor, Fernández Bolaños, Ricardo, Paolicelli, Damiano, Tortorella, Carla, Spelman, Tim, Margari, Lucia, Amato, Maria Pia, Comi, Giancarlo, Butzkueven, Helmut, Trojano, Maria, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, MUMC+: MA Med Staf Spec Neurologie (9), Klinische Neurowetenschappen, Morra, Vincenzo Brescia, Cabrera Gomez, Jose Antonio, and Bolaños, Ricardo Fernández
- Subjects
Registrie ,Male ,Multiple Sclerosis ,Adolescent ,Age of Onset ,Child ,Demyelinating Diseases ,Female ,Follow-Up Studies ,Humans ,Prognosis ,Retrospective Studies ,Risk Factors ,Disease Progression ,Registries ,Neurology ,Neurology (clinical) ,Prognosi ,ONSET MULTIPLE-SCLEROSIS ,CHILDHOOD ,CHILDREN ,PARACLINICAL FEATURES ,DISABILITY PROGRESSION ,NO ,Follow-Up Studie ,Retrospective Studie ,prognostic indicators ,Multiple Sclerosi ,pediatric, multiple sclerosis, prognosis, indicators ,OPTIC NEURITIS ,Risk Factor ,Demyelinating Disease ,NATURAL-HISTORY ,multiple sclerosis, clinically isolated syndrome, prognostic indicators ,TRANSVERSE MYELITIS ,clinically isolated syndrome ,INTERFERON BETA-1B ,Settore MED/26 - Neurologia ,FOLLOW-UP ,Human - Abstract
To assess prognostic factors for a second clinical attack and a first disability worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of Multiple Sclerosis (MS) patients. Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical attack (hazard ratio [HR], 95% confidence interval [CI] = 1.28, 1.06â1.55; 1.42, 1.10â1.84, respectively), whereas disease-modifying drug (DMD) exposure reduced this risk (HR, 95% CI = 0.75, 0.60â0.95). After pediatric onset MS (POMS) diagnosis, age at onset younger than 15 years and DMD exposure decreased the risk of a first Expanded Disability Status Scale (EDSS)-worsening event (HR, 95% CI = 0.59, 0.42â0.83; 0.75, 0.71â0.80, respectively), whereas the occurrence of relapse increased this risk (HR, 95% CI = 5.08, 3.46â7.46). An exploratory RECPAM analysis highlighted a significantly higher incidence of a first EDSS-worsening event in patients with multifocal or isolated spinal cord or optic neuritis involvement at onset in comparison to those with an isolated supratentorial or brainstem syndrome. A Cox regression model including RECPAM classes confirmed DMD exposure as the most protective factor against EDSS-worsening events and relapses as the most important risk factor for attaining EDSS worsening. Interpretation: This work represents a step forward in identifying predictors of unfavorable course in pCIS and POMS and supports a protective effect of early DMD treatment in preventing MS development and disability accumulation in this population. Ann Neurol 2017;81:729â739.
- Published
- 2017
10. Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
- Author
-
Patti, Francesco, Zimatore, Giovanni Bosco, Brescia Morra, Vincenzo, Aguglia, Umberto, Bossio, Roberto Bruno, Marziolo, Roberto, Valentino, Paola, Chisari, Clara Grazia, Capacchione, Antonio, and Zappia, Mario
- Subjects
- *
INTERFERONS , *MULTIPLE sclerosis - Abstract
Background: Subcutaneous recombinant interferon-beta 1a (IFN-β1a SC) is indicated for treatment of relapsing multiple sclerosis (RMS); however, it is associated with development of flu-like syndrome (FLS) in 75% of patients. No recommendations are available on whether evening or morning administration could induce better or worse FLS. Objective: Primary objective was to investigate whether morning administration of IFN-β1a 44 µg (Rebif) would affect the severity of FLS versus evening administration, in patients with RMS. Secondary objectives were to investigate whether timing of administration could lead to a better quality of life. Methods: Multicenter, open-label, 12-week, randomized, controlled, parallel-group, phase 4 study. Results: Of 217 patients screened at 29 Italian sites, 200 were included in the study. Among these, 104 patients were randomized to IFN-β1a SC administration in the morning and 96 in the evening. Morning administration resulted in higher FLS scores, as measured by the Multiple Sclerosis Treatment Concern Questionnaire, at week 4 (p = 0.0083) and week 8 (p = 0.0079); however, the difference was no longer significant at the end of 12 weeks. Conclusion: IFN-β1a evening injections in the first 8 weeks of treatment led to an improvement in FLS; when continuing therapy, time of administration could be decided according to patient's lifestyle and preference. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Prognostic indicators in pediatric clinically isolated syndrome.
- Author
-
UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Iaffaldano, Pietro, Simone, Marta, Lucisano, Giuseppe, Ghezzi, Angelo, Coniglio, Gabriella, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Lugaresi, Alessandra, Izquierdo, Guillermo, Bergamaschi, Roberto, Cabrera-Gomez, Jose Antonio, Pozzilli, Carlo, Millefiorini, Enrico, Alroughani, Raed, Boz, Cavit, Pucci, Eugenio, Zimatore, Giovanni Bosco, Sola, Patrizia, Lus, Giacomo, Maimone, Davide, Avolio, Carlo, Cocco, Eleonora, Sajedi, Seyed Aidin, Costantino, Gianfranco, Duquette, Pierre, Shaygannejad, Vahid, Petersen, Thor, Fernández Bolaños, Ricardo, Paolicelli, Damiano, Tortorella, Carla, Spelman, Tim, Margari, Lucia, Amato, Maria Pia, Comi, Giancarlo, Butzkueven, Helmut, Trojano, Maria, Van Pesch, Vincent, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Iaffaldano, Pietro, Simone, Marta, Lucisano, Giuseppe, Ghezzi, Angelo, Coniglio, Gabriella, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Lugaresi, Alessandra, Izquierdo, Guillermo, Bergamaschi, Roberto, Cabrera-Gomez, Jose Antonio, Pozzilli, Carlo, Millefiorini, Enrico, Alroughani, Raed, Boz, Cavit, Pucci, Eugenio, Zimatore, Giovanni Bosco, Sola, Patrizia, Lus, Giacomo, Maimone, Davide, Avolio, Carlo, Cocco, Eleonora, Sajedi, Seyed Aidin, Costantino, Gianfranco, Duquette, Pierre, Shaygannejad, Vahid, Petersen, Thor, Fernández Bolaños, Ricardo, Paolicelli, Damiano, Tortorella, Carla, Spelman, Tim, Margari, Lucia, Amato, Maria Pia, Comi, Giancarlo, Butzkueven, Helmut, Trojano, Maria, and Van Pesch, Vincent
- Abstract
To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients.
- Published
- 2017
12. The Progression of Posterior Cortical Atrophy to Corticobasal Syndrome: Lumping or Splitting Neurodegenerative Diseases?
- Author
-
Giorelli, Maurizio, Losignore, Nunzia Alessandra, Bagnoli, Junia, Difazio, Pasquale, and Zimatore, Giovanni Bosco
- Subjects
lcsh:Diseases of the musculoskeletal system ,Posterior cortical atrophy ,genetic structures ,FOS: Clinical medicine ,Neurosciences ,SPECT (Single Photon Emission Computed Tomography) ,magnetic resonance imaging ,Case Reports ,corticobasal syndrome ,lcsh:RC925-935 ,Alzheimer's disease ,lcsh:Neurology. Diseases of the nervous system ,lcsh:RC346-429 - Abstract
Background: Posterior cortical atrophy is a clinical syndrome that is characterized by the progressive loss of visuospatial integration and is associated with neurodegenerative conditions. Case Report: We describe a 60‐year‐old female with simultanagnosia, oculomotor apraxia, and optic ataxia for which she received an initial clinical diagnosis of posterior cortical atrophy. Three years later, she developed Balint's syndrome, Gerstmann's syndrome, left alien hand syndrome, smooth asymmetric (left) rigidity, cortical sensory loss, and spontaneous myoclonic jerks of the left arm, which suggested a final diagnosis of corticobasal syndrome. Discussion: This case report indicates that corticobasal syndrome may present with visuospatial deficits., Tremor and Other Hyperkinetic Movements, Tremor and Other Hyperkinetic Movements
- Published
- 2014
13. Change in Non-Motor Symptoms in Parkinson’s Disease and Essential Tremor Patients: A One-year Follow-up Study
- Author
-
Giorelli, Maurizio, Bagnoli, Junia, Consiglio, Luigi, Difazio, Pasquale, Zizza, Daniela, and Zimatore, Giovanni Bosco
- Subjects
lcsh:Diseases of the musculoskeletal system ,FOS: Clinical medicine ,Parkinson's disease ,Neurosciences ,follow-up ,Brief Reports ,Non-motor symptoms ,lcsh:RC925-935 ,NMSQuest ,essential tremor ,lcsh:Neurology. Diseases of the nervous system ,lcsh:RC346-429 - Abstract
Background: Non‐motor symptoms (NMS) in Parkinson's disease (PD) differ from those in essential tremor (ET), even before a definitive diagnosis is made. It is not clear whether patient's knowledge of the diagnosis and treatment influence their subsequent reporting of NMS. Methods: 1 year after a clinical and instrumental diagnosis, we compared the motor impairment (Movement Disorders Society (MDS)‐Unified Parkinson's Disease Rating Scale‐III) and non‐motor symptoms (NMSQuest) in PD (n = 31) and ET (n = 21) patients. Results: PD patients reported more NMS than did the ET patients (p = 0.002). When compared to their baseline report, at follow‐up, PD patients reported less nocturia (p = 0.02), sadness (p = 0.01), insomnia (p = 0.02), and restless legs (p = 0.04) and more nausea (p = 0.024), unexplained pain (p = 0.03), weight change (p = 0.009), and daytime sleepiness (p = 0.03). When compared to their baseline report, ET patients reported less loss of interest (p = 0.03), anxiety (p = 0.006), and insomnia (p = 0.02). Differences in reported weight change (p, Tremor and Other Hyperkinetic Movements, Tremor and Other Hyperkinetic Movements
- Published
- 2014
- Full Text
- View/download PDF
14. A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients
- Author
-
Niccolai, Claudia, primary, Portaccio, Emilio, additional, Goretti, Benedetta, additional, Hakiki, Bahia, additional, Giannini, Marta, additional, Pastò, Luisa, additional, Righini, Isabella, additional, Falautano, Monica, additional, Minacapelli, Eleonora, additional, Martinelli, Vittorio, additional, Incerti, Chiara, additional, Nocentini, Ugo, additional, Fenu, Giuseppe, additional, Cocco, Eleonora, additional, Marrosu, Maria Giovanna, additional, Garofalo, Elisa, additional, Ambra, Ferdinando Ivano, additional, Maddestra, Maurizio, additional, Consalvo, Marilena, additional, Viterbo, Rosa Gemma, additional, Trojano, Maria, additional, Losignore, Nunzia Alessandra, additional, Zimatore, Giovanni Bosco, additional, Pietrolongo, Erika, additional, Lugaresi, Alessandra, additional, Pippolo, Lorena, additional, Roscio, Marco, additional, Ghezzi, Angelo, additional, Castellano, Debora, additional, Stecchi, Sergio, additional, and Amato, Maria Pia, additional
- Published
- 2015
- Full Text
- View/download PDF
15. The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population
- Author
-
Goretti, Benedetta, primary, Niccolai, Claudia, additional, Hakiki, Bahia, additional, Sturchio, Andrea, additional, Falautano, Monica, additional, Minacapelli, Eleonora, additional, Martinelli, Vittorio, additional, Incerti, Chiara, additional, Nocentini, Ugo, additional, Murgia, Monica, additional, Fenu, Giuseppe, additional, Cocco, Eleonora, additional, Marrosu, Maria Giovanna, additional, Garofalo, Elisabetta, additional, Ambra, Ferdinando Ivano, additional, Maddestra, Maurizio, additional, Consalvo, Marilena, additional, Viterbo, Rosa Gemma, additional, Trojano, Maria, additional, Losignore, Nunzia Alessandra, additional, Zimatore, Giovanni Bosco, additional, Pietrolongo, Erika, additional, Lugaresi, Alessandra, additional, Langdon, Dawn, additional, Portaccio, Emilio, additional, and Amato, Maria Pia, additional
- Published
- 2014
- Full Text
- View/download PDF
16. Change in Non-motor Symptoms in Parkinson’s Disease and Essential Tremor Patients: A One-year Follow-up Study
- Author
-
Giorelli, Maurizio, primary, Bagnoli, Junia, additional, Consiglio, Luigi, additional, Difazio, Pasquale, additional, Zizza, Daniela, additional, and Zimatore, Giovanni Bosco, additional
- Published
- 2014
- Full Text
- View/download PDF
17. Hairdresser’s Dystonia: An Unusual Occupational Dystonia
- Author
-
Giorelli, Maurizio, primary and Zimatore, Giovanni Bosco, additional
- Published
- 2013
- Full Text
- View/download PDF
18. Interferon beta in relapsing–remitting multiple sclerosis: an independent postmarketing study in southern Italy.
- Author
-
Trojano, Maria, Liguori, Maria, Paolicelli, Damiano, Zimatore, Giovanni Bosco, De Robertis, Francesca, Avolio, Carlo, Giuliani, Fabrizio, Fuiani, Aurora, Livrea, Paolo, and For The Southern Italy MS Group
- Subjects
INTERFERONS ,MULTIPLE sclerosis ,DISEASE relapse ,STATISTICAL correlation - Abstract
This independent, population–based surveillance study monitored the efficacy and safety of interferon beta (IFNβ) products in 1033 patients with relapsing-remitting multiple sclerosis (RRMS) from 15 centres in Italy. Relapses, Expanded Disability Status Scale (EDSS) scores, and adverse events were evaluated for up to 24 months. Data of patients with a baseline EDSS score ≤3.5 are reported. The proportions of relapse-free patients were similar among the groups at 12 and 24 months (P=0.10). IFNβ products produced significant reductions from baseline in relapse rates at 12 and 24 months (P<0.001), with no differences among treatments (P=0.2). There were no significant differences in mean EDSS change among groups at 12 or 24 months. The IFNβ-1b group showed a higher incidence of adverse events during the first year of treatment (P<0.05) than IFNβ-1a groups, and more withdrawals (10%) compared with Avonex (5%) at 24 months. IFNβ products are equally effective in low disability RRMS, but IFNβ-1a may have a more favorable efficacy/tolerability ratio. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
19. Heterogeneous models for blood-cerebrospinal fluid barrier permeability to serum proteins in normal and abnormal cerebrospinal fluid/serum protein concentration gradients
- Author
-
Livrea, Paolo, primary, Trojano, Maria, additional, Simone, Isabella Laura, additional, Zimatore, Giovanni Bosco, additional, Pisicchio, Lorenza, additional, Logroscino, Giancarlo, additional, and Cibelli, Giuseppe, additional
- Published
- 1984
- Full Text
- View/download PDF
20. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
- Author
-
Maria Pia Sormani, Marco Capobianco, Matilde Inglese, Emanuele Angelucci, Rosanna Scimè, Raffaella Greco, Salvatore Cottone, Giancarlo Comi, Antonio Bertolotto, Alessio Signori, Riccardo Saccardi, Luca Massacesi, Lucia Moiola, Jessica Frau, Antonio Uccelli, Marco De Gobbi, Anna Maria Repice, Maria Pia Amato, Fabio Ciceri, Alice Mariottini, G. B. Zimatore, Francesca Gualandi, Gianluigi Mancardi, Giacomo Boffa, Chiara Innocenti, Boffa, Giacomo, Massacesi, Luca, Inglese, Matilde, Mariottini, Alice, Capobianco, Marco, Lucia, Moiola, Amato, Maria Pia, Cottone, Salvatore, Gualandi, Francesca, De Gobbi, Marco, Greco, Raffaella, Scimè, Rosanna, Frau, Jessica, Zimatore, Giovanni Bosco, Bertolotto, Antonio, Comi, Giancarlo, Uccelli, Antonio, Signori, Alessio, Angelucci, Emanuele, Innocenti, Chiara, Ciceri, Fabio, Repice, Anna Maria, Sormani, Maria Pia, Saccardi, Riccardo, and Mancardi, Gianluigi
- Subjects
Oncology ,0301 basic medicine ,Melphalan ,medicine.medical_specialty ,Expanded Disability Status Scale ,business.industry ,Multiple sclerosis ,medicine.medical_treatment ,Hazard ratio ,Hematopoietic stem cell transplantation ,medicine.disease ,Confidence interval ,Term (time) ,Transplantation ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Internal medicine ,Medicine ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Etoposide ,medicine.drug - Abstract
ObjectiveTo determine whether autologous hematopoietic stem cell transplantation (aHSCT) is able to induce durable disease remission in people with multiple sclerosis (MS), we analyzed the long-term outcomes after transplantation in a large cohort of patients with MS.MethodsTo be included, a minimum dataset (consisting of age, MS phenotype, Expanded Disability Status Scale [EDSS] score at baseline, information on transplantation technology, and at least 1 follow-up visit after transplantation) was required.ResultsTwo hundred ten patients were included (relapsing-remitting [RR] MS 122 [58%]). Median baseline EDSS score was 6 (1–9); mean follow-up was 6.2 (±5.0) years. Among patients with RRMS, disability worsening–free survival (95% confidence interval [CI]) was 85.5% (76.9%–94.1%) at 5 years and 71.3% (57.8%–84.8%) at 10 years. In patients with progressive MS, disability worsening–free survival was 71.0% (59.4%–82.6%) and 57.2% (41.8%–72.7%) at 5 and 10 years, respectively. In patients with RRMS, EDSS significantly reduced after aHSCT (p = 0.001; mean EDSS change per year −0.09 [95% CI −0.15% to −0.04%]). In patients with RRMS, the use of the BCNU+Etoposide+Ara-C+Melphalan (BEAM) + anti-thymocyte globulin (ATG) conditioning protocol was independently associated with a reduced risk of no evidence of disease activity 3 failure (hazard ratio 0.27 [95% CI 0.14–0.50], p < 0.001). Three patients died within 100 days from aHSCT (1.4%); no deaths occurred in patients transplanted after 2007.ConclusionsaHSCT prevents disability worsening in the majority of patients and induces durable improvement in disability in patients with RRMS. The BEAM + ATG conditioning protocol is associated with a more pronounced suppression of clinical relapses and MRI inflammatory activity.Classification of EvidenceThis study provides Class IV evidence that for people with MS, aHSCT induces durable disease remission in most patients.
- Published
- 2021
21. A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients
- Author
-
Chiara Concetta Incerti, Erika Pietrolongo, Debora Castellano, Bahia Hakiki, Vittorio Martinelli, Emilio Portaccio, Maurizio Maddestra, Monica Falautano, Maria Pia Amato, G. B. Zimatore, Ugo Nocentini, Claudia Niccolai, Elisabetta Garofalo, Rosa Gemma Viterbo, Isabella Righini, Lorena Pippolo, Eleonora Cocco, Marilena Consalvo, Marta Giannini, Benedetta Goretti, Maria Trojano, Sergio Stecchi, Eleonora Minacapelli, Maria Giovanna Marrosu, Alessandra Lugaresi, Nunzia Alessandra Losignore, Angelo Ghezzi, Marco Roscio, Giuseppe Fenu, Ferdinando Ivano Ambra, Luisa Pastò, Niccolai, Claudia, Portaccio, Emilio, Goretti, Benedetta, Hakiki, Bahia, Giannini, Marta, Pastò, Luisa, Righini, Isabella, Falautano, Monica, Minacapelli, Eleonora, Martinelli, Vittorio, Incerti, Chiara, Nocentini, Ugo, Fenu, Giuseppe, Cocco, Eleonora, Marrosu, Maria Giovanna, Garofalo, Elisa, Ambra, Ferdinando Ivano, Maddestra, Maurizio, Consalvo, Marilena, Viterbo, Rosa Gemma, Trojano, Maria, Losignore, Nunzia Alessandra, Zimatore, Giovanni Bosco, Pietrolongo, Erika, Lugaresi, Alessandra, Pippolo, Lorena, Roscio, Marco, Ghezzi, Angelo, Castellano, Debora, Stecchi, Sergio, and Amato, Maria Pia
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Psychometrics ,Paced Auditory Serial Addition Test ,Clinical Neurology ,Audiology ,Neuropsychological Tests ,Cognition Disorders ,Female ,Humans ,Middle Aged ,Cognition Disorder ,Multiple Sclerosi ,Medicine ,Neuropsychological assessment ,Psychiatry ,Assessment tool ,Brief international cognitive assessment for multiple sclerosis ,Cognitive impairment ,Multiple sclerosis ,Neurology (clinical) ,medicine.diagnostic_test ,business.industry ,Neuropsychology ,Cognition ,General Medicine ,Brief international cognitive assessment for multiple sclerosi ,medicine.disease ,Cognitive test ,Test (assessment) ,Settore MED/26 - Neurologia ,Neuropsychological Test ,business ,Psychometric ,Human ,Research Article - Abstract
Background: Recently, a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) has been developed as an international and standardized brief cognitive test, which is easily performed in everyday clinical practice for neuropsychological assessment in multiple sclerosis (MS). However, we need to gather more information about this tool compared to other neuropsychological batteries. The aim of our study is to compare the performance of BICAMS and Brief Repeatable Battery (BRB) in MS subjects. Methods: Tests of the BRB and BICAMS were administered to MS patients recruited from 11 Italian MS centres. Cognitive impairment (CI) was defined as the failure on at least two tests (scores below the fifth percentile) on the BRB and as the failure on at least one test of the BICAMS. The agreement between the performances on the two batteries was assessed through Cohen's K statistic. Finally we calculated the effects sizes for each test of the two batteries using Cohen's d. Results: The two batteries were administered to 192 MS patients (142 women, 50 men; mean age 41.4 ± 10.8 years, mean education 12.3 ± 3.5 years). Mean scores of patients were lower compared to those of healthy subjects in all the cognitive measures examined. Forty-six MS patients were identified as impaired and 48 as unimpaired on both of the batteries, when the Symbol Digit Modalities Test (SDMT) was included in the analysis. Cohen's K statistic was 0.46 which corresponds to a moderate accord. If the SDMT was excluded from the BRB, 37 MS patients were identified as impaired and 57 as unimpaired on both of the batteries. Cohen's K statistic was 0.3 which corresponds to a poor accord. The SDMT, the Paced Auditory Serial Addition Test (PASAT) 3 and 2 yielded higher d values (SDMT 0.83, PASAT 3 0.65, PASAT 2 0.84). Conclusions: This study confirms the feasibility of BICAMS in everyday clinical practice for the identification of CI and highlights the good psychometric properties of the SDMT.
- Published
- 2015
22. Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
- Author
-
Massarotti C, Sbragia E, Boffa G, Vercelli C, Zimatore GB, Cottone S, Frau J, Raiola A, Varaldo R, Mancardi G, Inglese M, and Anserini P
- Subjects
- Aged, Female, Fertility, Humans, Menstrual Cycle, Transplantation Conditioning, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation adverse effects, Multiple Sclerosis therapy
- Abstract
Data on fertility after autologous hematopoietic stem cell transplantation (aHSCT) in women with multiple sclerosis (MS) are inconclusive. This study aims to report on post-aHSCT menstrual resumption in a multi-center MS-women cohort. Out of 43 women, 30 (70%) recovered menses after a mean time of 6.8 months. Older age (odds ratio (OR) = 0.5, p < 0.0001) and previous pulsed cyclophosphamide (OR = 0.44, p = 0.005) were independently associated with a reduced menstrual recovery probability. Conditioning regimens' intensity resulted not associated with post-procedure amenorrhea. Our results highlight younger age as significantly associated with menses recovery; proper fertility counseling for MS women candidated to aHSCT both prior- and post-transplantation is therefore warranted.
- Published
- 2021
- Full Text
- View/download PDF
23. Prognostic indicators in pediatric clinically isolated syndrome.
- Author
-
Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, and Trojano M
- Subjects
- Adolescent, Age of Onset, Child, Demyelinating Diseases diagnostic imaging, Demyelinating Diseases physiopathology, Female, Follow-Up Studies, Humans, Male, Multiple Sclerosis diagnostic imaging, Multiple Sclerosis physiopathology, Prognosis, Retrospective Studies, Risk Factors, Demyelinating Diseases diagnosis, Disease Progression, Multiple Sclerosis diagnosis, Registries
- Abstract
Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients., Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data., Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical attack (hazard ratio [HR], 95% confidence interval [CI] = 1.28, 1.06-1.55; 1.42, 1.10-1.84, respectively), whereas disease-modifying drug (DMD) exposure reduced this risk (HR, 95% CI = 0.75, 0.60-0.95). After pediatric onset MS (POMS) diagnosis, age at onset younger than 15 years and DMD exposure decreased the risk of a first Expanded Disability Status Scale (EDSS)-worsening event (HR, 95% CI = 0.59, 0.42-0.83; 0.75, 0.71-0.80, respectively), whereas the occurrence of relapse increased this risk (HR, 95% CI = 5.08, 3.46-7.46). An exploratory RECPAM analysis highlighted a significantly higher incidence of a first EDSS-worsening event in patients with multifocal or isolated spinal cord or optic neuritis involvement at onset in comparison to those with an isolated supratentorial or brainstem syndrome. A Cox regression model including RECPAM classes confirmed DMD exposure as the most protective factor against EDSS-worsening events and relapses as the most important risk factor for attaining EDSS worsening., Interpretation: This work represents a step forward in identifying predictors of unfavorable course in pCIS and POMS and supports a protective effect of early DMD treatment in preventing MS development and disability accumulation in this population. Ann Neurol 2017;81:729-739., (© 2017 American Neurological Association.)
- Published
- 2017
- Full Text
- View/download PDF
24. Do non-motor symptoms in Parkinson's disease differ from essential tremor before initial diagnosis? A clinical and scintigraphic study.
- Author
-
Giorelli M, Bagnoli J, Consiglio L, Lopane M, Zimatore GB, Zizza D, and Difazio P
- Subjects
- Aged, Cocaine analogs & derivatives, Essential Tremor diagnostic imaging, Female, Humans, Male, Middle Aged, Parkinson Disease diagnostic imaging, Radiopharmaceuticals, Tomography, Emission-Computed, Single-Photon, Essential Tremor complications, Parkinson Disease complications
- Abstract
Background: Non-motor symptoms (NMS) in Parkinson's disease (PD) are common, increase the patients' disability and have a significantly negative impact on their quality of life. Essential tremor (ET) is also affected by non-motor symptoms and often enters into the differential diagnosis with PD. Brain scintigraphy with [(123)I]β-CIT SPECT is a technique used to facilitate differential diagnosis between PD and ET., Methods: We evaluated both motor impairment (MDS-UPDRS-III) and non-motor symptoms (NMSQuest) in patients who underwent a [(123)I]β-CIT SPECT examination for diagnostic purposes. Both the clinical and the scintigraphic data obtained from the selected PD (n = 31) and ET (n = 22) patients were compared., Results: We did not detect a significant difference in the total number of NMS reported by either PD (10.4 ± 4.9) or ET patients (8.41 ± 3.3). PD patients reported more drooling (29%), hyposmia (32.2%), hallucinations (19.3%), difficulty in concentrating (51.6%), orthostatic dizziness (67.7%), falling (19.3%), vivid dreams (32.2%), REM sleep behavior disorder (58%), and diplopia (22.5%) compared with ET patients. PD patients who complained of drooling, orthostatic dizziness, and diplopia had greater denervation of the caudata than did the PD patients who did not report the same symptoms. The differences observed were not associated with differences in age, sex, UPDRS-III score, and the presence/absence of tremor., Conclusions: The declaration of non-motor symptoms is influenced by subjective factors that are widely suggestible. When analyzed early and before receiving a definitive diagnosis, PD patients complain of specific symptoms that seem to depend on different pathogenetic mechanisms., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.